306 related articles for article (PubMed ID: 30131605)
1. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Dhawan M; Ryan CJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
4. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
5. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
6. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
[TBL] [Abstract][Full Text] [Related]
7. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for homologous recombination-deficient prostate cancer.
Christenson ES; Antonarakis ES
Expert Opin Emerg Drugs; 2018 Jun; 23(2):123-133. PubMed ID: 29595348
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
10. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
11. Emerging PARP inhibitors for treating breast cancer.
Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
[TBL] [Abstract][Full Text] [Related]
12. [DNA repair as a therapeutic target].
Eberst L; Brahmi M; Cassier PA
Bull Cancer; 2017 Nov; 104(11):988-998. PubMed ID: 29132681
[TBL] [Abstract][Full Text] [Related]
13. A profile on the FoundationFocus CDxBRCA tests.
Ford L; Wolford JE; Brown SM; Randall LM
Expert Rev Mol Diagn; 2020 Mar; 20(3):285-292. PubMed ID: 32028808
[No Abstract] [Full Text] [Related]
14. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
16. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
17. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
Cimadamore A; Lopez-Beltran A; Massari F; Santoni M; Mazzucchelli R; Scarpelli M; Galosi AB; Cheng L; Montironi R
Future Oncol; 2020 Feb; 16(5):75-80. PubMed ID: 31916449
[No Abstract] [Full Text] [Related]
18. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
19. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]